Jean Bourhis reports on key results from ESMO Virtual Congress 2020 on LBA38: Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial
Produced by ESMO, https://oncologypro.esmo.org